Precision Oncology in Gastrointestinal and Colorectal Cancer Surgery
Surg Oncol Clin N Am. 2024 Apr;33(2):321-341. doi: 10.1016/j.soc.2023.12.007. Epub 2024 Jan 9.ABSTRACTPrecision medicine is used to treat gastrointestinal malignancies including esophageal, gastric, small bowel, colorectal, and pancreatic cancers. Cutting-edge assays to detect and treat these cancers are active areas of research and will soon become standard of care. Colorectal cancer is a prime example of precision oncology as disease site is no longer the final determinate of treatment. Here, the authors describe how leveraging an understanding of tumor biology translates to individualized patient care using evidence-bas...
Source: Clinical Colorectal Cancer - February 24, 2024 Category: Cancer & Oncology Authors: Hannah G McDonald Daniel M Kerekes Joseph Kim Sajid A Khan Source Type: research
Colorectal cancer treatment outcomes during the pandemic: Our experience of COVID-19 at a tertiary referral center
CONCLUSION: Presentation of patients with CRC varied, with a significant increase in symptomatic presentations and decreased numbers for surveillance. Through flexibility and change in practice, our institution helped improve access to surgical intervention and oncological therapies. Further prospective work is required to identify long-term outcomes and characterize the effects of ongoing disruptions.PMID:38391122 | DOI:10.1111/ajco.14051 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Christy Kei Richard Gartrell Yasser Arafat Elizabeth Degabriele Josephine Yeung Steven Chan Ian Faragher Justin M C Yeung Source Type: research
Rates of Compliance in South Indian American Communities of Southern California Regarding Cancer Screening
CONCLUSION: Understanding the cultural characteristics of special populations, such as Indian Americans, can help communities adhere to more effective screening practices that can improve outcomes.PMID:38391412 | PMC:PMC10888186 | DOI:10.3390/clinpract14010026 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Bhavana Seelam Ria Sandhu Mariam Alam Akhila Kethireddy Isain Zapata Source Type: research
Colorectal cancer treatment outcomes during the pandemic: Our experience of COVID-19 at a tertiary referral center
CONCLUSION: Presentation of patients with CRC varied, with a significant increase in symptomatic presentations and decreased numbers for surveillance. Through flexibility and change in practice, our institution helped improve access to surgical intervention and oncological therapies. Further prospective work is required to identify long-term outcomes and characterize the effects of ongoing disruptions.PMID:38391122 | DOI:10.1111/ajco.14051 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Christy Kei Richard Gartrell Yasser Arafat Elizabeth Degabriele Josephine Yeung Steven Chan Ian Faragher Justin M C Yeung Source Type: research
Rates of Compliance in South Indian American Communities of Southern California Regarding Cancer Screening
CONCLUSION: Understanding the cultural characteristics of special populations, such as Indian Americans, can help communities adhere to more effective screening practices that can improve outcomes.PMID:38391412 | DOI:10.3390/clinpract14010026 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 23, 2024 Category: Cancer & Oncology Authors: Bhavana Seelam Ria Sandhu Mariam Alam Akhila Kethireddy Isain Zapata Source Type: research
Tumour-associated macrophage-derived DOCK7-enriched extracellular vesicles drive tumour metastasis in colorectal cancer via the RAC1/ABCA1 axis
CONCLUSIONS: Overall, our findings suggest that DOCK7 delivered via TAM-EVs could regulate cholesterol metabolism in CRC cells and CRC cell metastasis through the RAC1/AKT/FOXO1/ABCA1 axis. DOCK7 could thus be a new therapeutic target for controlling CRC metastasis.PMID:38385857 | PMC:PMC10883245 | DOI:10.1002/ctm2.1591 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 22, 2024 Category: Cancer & Oncology Authors: Weiwei Chen Menghua Zhou Bingjie Guan Bowen Xie Youdong Liu Jiang He Jingjing Zhao Qian Zhao Dongwang Yan Source Type: research
Multiple duodenal epithelial tumors in a patient with polymerase proofreading-associated polyposis in POLE variant
Clin J Gastroenterol. 2024 Feb 22. doi: 10.1007/s12328-024-01922-1. Online ahead of print.ABSTRACTPolymerase proofreading-associated polyposis (PPAP) is a rare disease with autosomal-dominant inheritance caused by germline variants in the POLE and POLD1 genes. PPAP has been reported to increase the risk of multiple cancers, including colon, duodenal, and endometrial cancers. Herein, we report a case in which multiple duodenal tumors led to the detection of a POLE mutation. A 43-year-old woman underwent esophagogastroduodenoscopy (EGD). Multiple duodenal tumors were detected, and all lesions were treated endoscopically. The...
Source: Clinical Colorectal Cancer - February 22, 2024 Category: Cancer & Oncology Authors: Hajime Miyazaki Osamu Dohi Eiko Maeda Atsushi Tomioka Naohisa Yoshida Yukiko Morinaga Yoshito Itoh Hideki Ishikawa Source Type: research
Tumour-associated macrophage-derived DOCK7-enriched extracellular vesicles drive tumour metastasis in colorectal cancer via the RAC1/ABCA1 axis
CONCLUSIONS: Overall, our findings suggest that DOCK7 delivered via TAM-EVs could regulate cholesterol metabolism in CRC cells and CRC cell metastasis through the RAC1/AKT/FOXO1/ABCA1 axis. DOCK7 could thus be a new therapeutic target for controlling CRC metastasis.PMID:38385857 | DOI:10.1002/ctm2.1591 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 22, 2024 Category: Cancer & Oncology Authors: Weiwei Chen Menghua Zhou Bingjie Guan Bowen Xie Youdong Liu Jiang He Jingjing Zhao Qian Zhao Dongwang Yan Source Type: research
Multiple duodenal epithelial tumors in a patient with polymerase proofreading-associated polyposis in POLE variant
Clin J Gastroenterol. 2024 Feb 22. doi: 10.1007/s12328-024-01922-1. Online ahead of print.ABSTRACTPolymerase proofreading-associated polyposis (PPAP) is a rare disease with autosomal-dominant inheritance caused by germline variants in the POLE and POLD1 genes. PPAP has been reported to increase the risk of multiple cancers, including colon, duodenal, and endometrial cancers. Herein, we report a case in which multiple duodenal tumors led to the detection of a POLE mutation. A 43-year-old woman underwent esophagogastroduodenoscopy (EGD). Multiple duodenal tumors were detected, and all lesions were treated endoscopically. The...
Source: Clinical Colorectal Cancer - February 22, 2024 Category: Cancer & Oncology Authors: Hajime Miyazaki Osamu Dohi Eiko Maeda Atsushi Tomioka Naohisa Yoshida Yukiko Morinaga Yoshito Itoh Hideki Ishikawa Source Type: research
Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatellite-instable colorectal cancers
J Pathol Clin Res. 2024 Mar;10(2):e348. doi: 10.1002/cjp2.348.ABSTRACTUp to 30% of colorectal cancers (CRCs) develop from sessile serrated lesions (SSLs). Within the serrated neoplasia pathway, at least two principally distinct oncogenetic routes exist generating microsatellite-stable and microsatellite-instable CRCs, respectively. Aberrant DNA methylation (DNAm) is found early in the serrated pathway and might play a role in both oncogenetic routes. We studied a cohort of 23 SSLs with a small focus (<10 mm) of dysplasia or cancer, 10 of which were MLH1 deficient and 13 MLH1 proficient. By comparing, for each SSL, the m...
Source: Clinical Colorectal Cancer - February 21, 2024 Category: Cancer & Oncology Authors: David Efwm van Toledo Arne Gc Bleijenberg Andrea Venema Mireille J de Wit Susanne van Eeden Gerrit A Meijer Beatrice Carvalho Evelien Dekker Peter Henneman Joep Eg IJspeert Carel Jm van Noesel Source Type: research
Cost-effectiveness of surveillance intervals after curative resection of colorectal cancer
CONCLUSIONS: In stage I, the cost-effectiveness of intensive surveillance is very poor and strategy 4 is the most cost-effective. Strategy 3 is the most cost-effective in stages II and III.PMID:38376792 | DOI:10.1093/jjco/hyae018 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Yuji Takayama Shunsuke Tsukamoto Yozo Kudose Yasuyuki Takamizawa Konosuke Moritani Minoru Esaki Yukihide Kanemitsu Ataru Igarashi Source Type: research
Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer
CONCLUSIONS: Our results identify MIR652-3p as potential biomarker and as a driver of cell and non-cell autonomous mechanisms of resistance to regorafenib.PMID:38376926 | DOI:10.1158/1078-0432.CCR-23-2748 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Somaieh Hedayat Luciano Cascione David Cunningham Marta Schirripa Andrea Lampis Jens C Hahne Nina Tunariu Sung Pil Hong Silvia Marchetti Khurum Khan Elisa Fontana Valentina Angerilli Mia Delrieux Daniel Nava Rodrigues Letizia Procaccio Sheela Rao David Wa Source Type: research
Cost-effectiveness of surveillance intervals after curative resection of colorectal cancer
CONCLUSIONS: In stage I, the cost-effectiveness of intensive surveillance is very poor and strategy 4 is the most cost-effective. Strategy 3 is the most cost-effective in stages II and III.PMID:38376792 | DOI:10.1093/jjco/hyae018 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Yuji Takayama Shunsuke Tsukamoto Yozo Kudose Yasuyuki Takamizawa Konosuke Moritani Minoru Esaki Yukihide Kanemitsu Ataru Igarashi Source Type: research
Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer
CONCLUSIONS: Our results identify MIR652-3p as potential biomarker and as a driver of cell and non-cell autonomous mechanisms of resistance to regorafenib.PMID:38376926 | DOI:10.1158/1078-0432.CCR-23-2748 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Somaieh Hedayat Luciano Cascione David Cunningham Marta Schirripa Andrea Lampis Jens C Hahne Nina Tunariu Sung Pil Hong Silvia Marchetti Khurum Khan Elisa Fontana Valentina Angerilli Mia Delrieux Daniel Nava Rodrigues Letizia Procaccio Sheela Rao David Wa Source Type: research
Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer
CONCLUSIONS: This study showed class 1/non-class 1 BRAF mutation in CRC had significantly differences in co-mutation features, genomic markers and prognostic. Understanding BRAF mutation types and comutation mechanism will contribute to accurately grasping treatment and follow-up strategies and promoting the development of precision therapy for CRC in the future.PMID:38372057 | DOI:10.21037/cco-23-117 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 19, 2024 Category: Cancer & Oncology Authors: Yingying Huang Wenzhuo Jia Gang Zhao Yunbo Zhao Shuai Zhang Zhongkang Li Guoju Wu Source Type: research
